Foghorn Therapeutics Stock Performance
| FHTX Stock | USD 4.31 0.11 2.62% |
The firm shows a Beta (market volatility) of 1.4, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Foghorn Therapeutics will likely underperform. At this point, Foghorn Therapeutics has a negative expected return of -0.75%. Please make sure to confirm Foghorn Therapeutics' maximum drawdown, as well as the relationship between the daily balance of power and period momentum indicator , to decide if Foghorn Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Foghorn Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 2.62 | Five Day Return 2.38 | Year To Date Return (6.10) | Ten Year Return (76.21) | All Time Return (76.21) |
1 | We Think Foghorn Therapeutics Needs To Drive Business Growth Carefully | 11/06/2024 |
2 | Analysts Have Made A Financial Statement On Foghorn Therapeutics Inc.s Third-Quarter Report | 11/07/2024 |
3 | Wall Street Analysts See a 104.08 percent Upside in Foghorn Therapeutics Can the Stock Really Move This High | 11/25/2024 |
4 | This Foghorn Therapeutics Insider Reduced Their Stake By 13 | 12/12/2024 |
5 | Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities | 12/16/2024 |
6 | Insider Trading | 12/27/2024 |
7 | Short Interest in Foghorn Therapeutics Inc. Expands By 6.8 percent - MarketBeat | 01/02/2025 |
8 | Foghorn Therapeutics Loses -23.05 percent in 4 Weeks, Heres Why a Trend Reversal May be Around the Corner | 01/15/2025 |
| Begin Period Cash Flow | 53.9 M |
Foghorn |
Foghorn Therapeutics Relative Risk vs. Return Landscape
If you would invest 723.00 in Foghorn Therapeutics on October 20, 2024 and sell it today you would lose (292.00) from holding Foghorn Therapeutics or give up 40.39% of portfolio value over 90 days. Foghorn Therapeutics is currently does not generate positive expected returns and assumes 4.1182% risk (volatility on return distribution) over the 90 days horizon. In different words, 36% of stocks are less volatile than Foghorn, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Foghorn Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Foghorn Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Foghorn Therapeutics, and traders can use it to determine the average amount a Foghorn Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1811
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | FHTX |
Estimated Market Risk
| 4.12 actual daily | 36 64% of assets are more volatile |
Expected Return
| -0.75 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.18 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Foghorn Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Foghorn Therapeutics by adding Foghorn Therapeutics to a well-diversified portfolio.
Foghorn Therapeutics Fundamentals Growth
Foghorn Stock prices reflect investors' perceptions of the future prospects and financial health of Foghorn Therapeutics, and Foghorn Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Foghorn Stock performance.
| Return On Equity | -4.7 | ||||
| Return On Asset | -0.2 | ||||
| Operating Margin | (3.05) % | ||||
| Current Valuation | 5.16 M | ||||
| Shares Outstanding | 55.59 M | ||||
| Price To Book | 10.71 X | ||||
| Price To Sales | 9.39 X | ||||
| Revenue | 34.16 M | ||||
| Gross Profit | (82.3 M) | ||||
| EBITDA | (104.45 M) | ||||
| Net Income | (98.43 M) | ||||
| Cash And Equivalents | 373.5 M | ||||
| Cash Per Share | 8.94 X | ||||
| Total Debt | 45.07 M | ||||
| Debt To Equity | 2.19 % | ||||
| Current Ratio | 6.84 X | ||||
| Book Value Per Share | (0.51) X | ||||
| Cash Flow From Operations | (118.11 M) | ||||
| Earnings Per Share | (1.90) X | ||||
| Market Capitalization | 239.61 M | ||||
| Total Asset | 285.92 M | ||||
| Retained Earnings | (471.56 M) | ||||
| Working Capital | 181.75 M | ||||
About Foghorn Therapeutics Performance
Evaluating Foghorn Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Foghorn Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Foghorn Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.31) | (0.33) | |
| Return On Capital Employed | (0.43) | (0.45) | |
| Return On Assets | (0.31) | (0.33) | |
| Return On Equity | 1.47 | 1.54 |
Things to note about Foghorn Therapeutics performance evaluation
Checking the ongoing alerts about Foghorn Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Foghorn Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Foghorn Therapeutics generated a negative expected return over the last 90 days | |
| Foghorn Therapeutics has high historical volatility and very poor performance | |
| Foghorn Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 34.16 M. Net Loss for the year was (98.43 M) with loss before overhead, payroll, taxes, and interest of (82.3 M). | |
| Foghorn Therapeutics currently holds about 373.5 M in cash with (118.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Foghorn Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 72.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: Foghorn Therapeutics Loses -23.05 percent in 4 Weeks, Heres Why a Trend Reversal May be Around the Corner |
- Analyzing Foghorn Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Foghorn Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Foghorn Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Foghorn Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Foghorn Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Foghorn Therapeutics' stock. These opinions can provide insight into Foghorn Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Foghorn Stock Analysis
When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.